Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting Report. by Carrieri, D et al.
Ethical issues and best practice in clinically
based genomic research: Exeter Stakeholders
Meeting Report
D Carrieri,1 C Bewshea,2 G Walker,2 T Ahmad,2 W Bowen,3 A Hall,4 S Kelly,1
on behalf of the 7th of October 2015 Exeter Stakeholders Meeting
1Egenis, Department of
Sociology, Philosophy and
Anthropology, University of
Exeter, Exeter, UK
2IBD and Pharmacogenetics
Research Group, Royal Devon
and Exeter NHS Foundation
Trust, Exeter, UK
3Health Research Authority,
NHS, London, UK
4PHG Foundation, Cambridge,
UK
Correspondence to
Dr D Carrieri, Department of
Egenis, Sociology, Philosophy
and Anthropology, University
of Exeter, St German’s Rd,
Exeter EX4 4PJ, UK; d.
carrieri@exeter.ac.uk
Received 11 March 2016
Revised 2 June 2016
Accepted 6 September 2016
To cite: Carrieri D,
Bewshea C, Walker G, et al.
J Med Ethics Published
Online First: [please include
Day Month Year]
doi:10.1136/medethics-
2016-103530
ABSTRACT
Current guidelines on consenting individuals to
participate in genomic research are diverse. This creates
problems for participants and also for researchers,
particularly for clinicians who provide both clinical care
and research to their patients. A group of 14
stakeholders met on 7 October 2015 in Exeter to discuss
the ethical issues and the best practice arising in
clinically based genomic research, with particular
emphasis on the issue of returning results to study
participants/patients in light of research ﬁndings
affecting research and clinical practices. The group was
deliberately multidisciplinary to ensure that a diversity of
views was represented. This report outlines the main
ethical issues, areas of best practice and principles
underlying ethical clinically based genomic research
discussed during the meeting. The main point emerging
from the discussion is that ethical principles, rather than
being formulaic, should guide researchers/clinicians to
identify who the main stakeholders are to consult with
for a speciﬁc project and to incorporate their voices/
views strategically throughout the lifecycle of each
project. We believe that the mix of principles and
practical guidelines outlined in this report can contribute
to current debates on how to conduct ethical clinically
based genomic research.
Current guidelines on consenting individuals to
participate in genomic research are diverse.1 The
Research Governance Framework for Health and
Social Care 2004 provides guidance to protect the
dignity, rights, safety and well-being of research
participants and states that informed consent is at
the heart of ethical research.2 There is also some
guidance around consenting when using tissue
banks pertaining to the Human Tissue Act 2004,3
and very speciﬁc guidance from the Joint
Committee of Medical Ethics around consent in
medical genetics.4
However, there does not seem to be any guid-
ance available for researchers and certainly not for
participants concerning consent for genomic
research. This creates problems for participants,
who may not have the conﬁdence to give their
consent, and also for researchers/clinicians who
provide both clinical care and research to their
patients. Current approaches to consent do not suf-
ﬁciently take into account researchers’ or partici-
pants’ interests, and the speciﬁc issues that genomic
research raises; for example, this research often
blurs the boundaries with research and clinical
care.
A group of 14 stakeholders met on 7 October
2015 in Exeter to discuss the ethical issues and the
best practice arising in clinically based genomic
research, with particular emphasis on the issue of
returning results to study participants/patients in
light of research ﬁndings affecting research and
clinical practice. The group was deliberately multi-
disciplinary to cover diverse views and experiences.
It included a general practitioner (GP), patient
representatives, clinical genetic specialists, clinical
research team members, molecular biologists, a
lawyer, a genetic biobank manager, a representa-
tive of the Health Research Authority, members
of the local 100 000 Genomes team, social scien-
tists and ethicists. This meeting was organised as
part of a collaboration between the Exeter IBD
and Pharmacogenetics Research group and social
scientist at the University of Exeter. This collab-
orative project titled ‘Consent and clinical trials in
pharmacogenetics—facilitating the clinical im-
plementation of modern genetic technologies for
the treatment of patients with inﬂammatory
bowel disease was funded by the ESRC Impact
Cultivation Award.
We sought to identify both areas of best practice
and the underlying ethical principles of such
research. Our a priori agenda was to generate
ethical guiding principles that were ﬂexible rather
than formulaic, in order not to deter good quality
research and to enable it to be carried out ethically
(ie, to respect the interests and rights of the stake-
holders involved in the research process). We recog-
nise that similar efforts are being carried out by
other groups in the UK5 and other countries,6 indi-
cating the importance and timeliness of issues
involved, and the need for guidance, or at least
clarity.
CLINICALLY BASED GENOMIC RESEARCH AND
ETHICAL ISSUES
We identiﬁed that clinically based genomic research
carries particular characteristicsi, from which ethical
issues arise. Such research typically involves the
potentially complicated relationships of clinician/
researcher and patient/participant. The implications
of these relationships need to be taken into account
when research projects are designed.
iWe recognise that some of these characteristics are
germane to genomic research, and they are also relevant
to other types of research, for example, imaging studies.
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Feeding back individual ﬁndings to research participants, who
are also patients, may raise particular issues for clinicians,
researchers and participants concerning ongoing and future
treatment decisions. Participants’/patients’ genetic data are
potentially identiﬁable.
Genomic research has the potential to generate incidental
ﬁndings (IFs), that is, ﬁndings that were not an intended object-
ive of the study but were discovered as a consequence of the
current technologies employed in this ﬁeld. Such occurrences
are rare although the consequences of imparting this informa-
tion to study participants can be life-changing. It is difﬁcult
for clinicians and researchers to assess the validity and the
clinical relevance of these results, to attribute the appropriate
level of risk and to convey this information to participants in
a meaningful way. However, research ethics committees
expect clinicians and researchers to address the return of
research ﬁndings to participants/patients in their research pro-
posals (ie, to have a policy on returning summary or aggre-
gated research results).
Signiﬁcance and actionability criteria tend to be medically/
treatment driven. Researchers/clinicians and patients/participants
may have different views about the value of genetic information.
For example, some participants may wish to know about any
result generated by research—even if it is not clinically action-
able—as it may have a life-related value for them (they may
wish to have this knowledge for its own sake, for members of
their family, etc).
Primary care physicians—GPs in the UK—are normally
informed about their patients’ participation in research.
However, it is not clear what their roles and responsibilities are
in relation to this information, and other information generated
by genomic research. The custodianship of data and tissue
donated to research are not always clear to research partici-
pants/patients and clinicians/researchers. There is no ownership
of data and tissue, rather ownership of IP arising from analysis
of the aforementioned.
EXAMPLES OF BEST PRACTICE
We identiﬁed the following examples of best practice. In the
Nottingham Health Science Biobank (NHSB), experienced
patients help research teams to take consent and are also con-
sulted throughout research projects (eg, research teams seek
their feedback in relation to information materials given to
patients).7
The Exeter 10 000 project (EXTEND) biobank’s model of
governance uses a patient committee to approve researchers’
access to blood samples and participant data on behalf of all
participants, and contribute to the design of studies and infor-
mation materials given to patients.8
Embedding NHS research and development departments in
hospitals allows these departments to support research projects
and research teams more effectively.
PRINCIPLES AND PRACTICAL GUIDANCE
In terms of principles and practical guidance underlying ethical
clinically based genomic research, we identiﬁed the following.
Trust
Trust is a key component, although its inﬂuence can be both
positive and negative; established clinical relationships may both
foster trust between the patient and clinician/researcher which
facilitates research, but can also lead to a lack of clarity about
whether the activity is part of clinical care or research, and to
cutting corners in consent on both sides.
Consultation
Consent is a process; it should be understood to be adaptable
and consultative throughout the research project. Study
design should be informed by consultations with patients,
before patients are enrolled into the research. This would
allow the identiﬁcation of areas of concerns with regard to
the intended procedures and ethical issues pertaining to the
study. The key is genuine and timely consultation. Patient pre-
ferences regarding receiving primary and IFs will vary,
between individuals and over time, and ‘one size ﬁts all’
consent models and procedures should be avoided where pos-
sible. Approaches should take into account consultation and
dialogue with stakeholders, including other healthcare profes-
sionals who may be involved.
Patients with relevant experience of a condition, research and/
or treatment can be a valuable resource in the consent process.
For example, they can be consulted by researchers who are
setting up a new project to review participant-facing literature,
or they can work alongside with research teams to promote
interactive consenting processes.
Consultation should also include consulting the Health
Research Authority (or similar organisations in other countries)
to seek advice and guidance on acceptable practice.
Consent should not include promises regarding privacy and
control over personal information in the event of data sharing,
as they cannot be fulﬁlled. Patient/participant data cannot be
deidentiﬁed (eg, pseudoanonymised and anonymised) in the
clinical context, and data pathways should be transparent to par-
ticipants. Researchers should ensure that their information gov-
ernance is compliant with best current practices and legal
guidance.
GPs are suitably placed to hold research and clinical informa-
tion as their patient records are comprehensive, their IT systems
are advanced and patient information contained therein follows
the patient and is searchable (see eg, initiatives such as the
Clinical Practice Research Datalink9). Consideration of GPs’ role
in terms of conveying and acting upon this information should
be given.
Stakeholders, and how they are engaged, may vary depending
on the speciﬁc projects. Therefore, ethical principles and guide-
lines (such as above) should guide researchers to identify who
the main stakeholders are to consult with for a speciﬁc project
and to incorporate their voices/views strategically throughout
the lifecycle of the project. Ethical considerations should
promote an open dialogue between the main stakeholders and a
critical/genuine (as opposed to tokenistic) engagement of as
many relevant stakeholders as possible.
Training
Some stakeholders may need training to provide competencies
for participating in such consultations.
Technology
Ethical reasoning should not be tied too speciﬁcally to our
current technology and capacity as these will soon become
outdated.
The stakeholder meeting prompted the manager of the Exeter
10 000 project (EXTEND) biobank to consider how to respon-
sibly prepare for the possibility of whole genome sequencing
being conducted on the donors’ tissue. The manager changed
the information sheet and consent materials by adding more
information and by making it more logistically easy for donors
to withdraw consent. More generally, the meeting helped to
2 Carrieri D, et al. J Med Ethics 2016;0:1–3. doi:10.1136/medethics-2016-103530
Brief report
group.bmj.com on October 19, 2016 - Published by http://jme.bmj.com/Downloaded from 
establish links between different stakeholders and to lay the
ground for future consultations.
It is our hope that this meeting report will inform other
similar discussions about ethical issues in clinically based
genomic research and we welcome responses.
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